<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600909</url>
  </required_header>
  <id_info>
    <org_study_id>17-498</org_study_id>
    <nct_id>NCT03600909</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia</brief_title>
  <official_title>A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to see if the study therapy can decrease the chemotherapy-related&#xD;
      side effects while maximizing the effectiveness of disease control. The physicians will also&#xD;
      be studying the effect of removing T-cells from the donor&quot;s stem cells before transplant.&#xD;
      T-cells are a type of white blood cell that may help cause a serious side effect of&#xD;
      transplant called Graft versus Host Disease (GVHD). The way it removes the T-cells from the&#xD;
      donor stem cells is actually by selecting only the stem cells (called CD34 cells) by using a&#xD;
      device called CliniMACS. This process is called CD34 selection. The CliniMACS® device is&#xD;
      currently under the supervision of the FDA .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Actual">April 9, 2021</completion_date>
  <primary_completion_date type="Actual">April 9, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A three-arm phase II treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and disease-free survival following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine and ATG</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Failure or Rejection</measure>
    <time_frame>5 years</time_frame>
    <description>Primary non-engraftment is diagnosed when the patient fails to achieve an ANC ≥500/µl at any time in the first 28 days post-transplant. If (1) after achievement of an ANC ≥500/mm^3, the ANC declines to &lt;500/mm^3 for more than 3 consecutive days in the absence of relapse, or, (2) there is absence of donor cells in the marrow and/or blood as demonstrated by chimerism assay in the absence of relapse, a diagnosis of secondary graft failure is made. The patient is not evaluable for graft failure or rejection if recurrence of host MDS is detected concurrently.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Fanconi Anemia</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <condition>Acute Myelogenous Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Good Risk Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 18 years old or younger with marrow aplasia or single lineage cytopenias (Arm A) will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.6-0.8 mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate risk patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 18 years old or younger with MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8-1.0mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 19 years old or older with marrow aplasia or MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.4mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).&#xD;
A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.&#xD;
A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.</description>
    <arm_group_label>Good Risk Patients</arm_group_label>
    <arm_group_label>High risk patients</arm_group_label>
    <arm_group_label>Intermediate risk patients</arm_group_label>
    <other_name>busulfex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.</description>
    <arm_group_label>Good Risk Patients</arm_group_label>
    <arm_group_label>High risk patients</arm_group_label>
    <arm_group_label>Intermediate risk patients</arm_group_label>
    <other_name>FLUDARA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.</description>
    <arm_group_label>Good Risk Patients</arm_group_label>
    <arm_group_label>High risk patients</arm_group_label>
    <arm_group_label>Intermediate risk patients</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin (Rabbit)</intervention_name>
    <description>Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment</description>
    <arm_group_label>Good Risk Patients</arm_group_label>
    <arm_group_label>High risk patients</arm_group_label>
    <arm_group_label>Intermediate risk patients</arm_group_label>
    <other_name>hymoglobulin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The CliniMACS device</intervention_name>
    <description>The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)</description>
    <arm_group_label>Good Risk Patients</arm_group_label>
    <arm_group_label>High risk patients</arm_group_label>
    <arm_group_label>Intermediate risk patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>All patients will also receive G-CSF post-transplant to foster engraftment.</description>
    <arm_group_label>Good Risk Patients</arm_group_label>
    <arm_group_label>High risk patients</arm_group_label>
    <arm_group_label>Intermediate risk patients</arm_group_label>
    <other_name>Granulocyte colony-stimulating factor, filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a diagnosis of Fanconi anemia (confirmed by mitomycin C or&#xD;
             diepoxybutane [DEB] chromosomal breakage testing at a CLIA approved laboratory).&#xD;
&#xD;
        Patients must have one of the following hematologic diagnoses:&#xD;
&#xD;
        1. Severe Aplastic Anemia (SAA), with bone marrow cellularity of &lt;25% OR Severe Isolated&#xD;
        Single lineage Cytopenia&#xD;
&#xD;
        AND at least one of the following features:&#xD;
&#xD;
          1. Platelet count &lt;20 x 10^9/L or platelet transfusion dependence*&#xD;
&#xD;
          2. ANC &lt;1000 x 10^9/L&#xD;
&#xD;
          3. Hgb &lt;8 gm/dl or red cell transfusion dependence*&#xD;
&#xD;
        2. Myelodysplastic Syndrome (MDS) (Appendix 1: MDS Classification)&#xD;
&#xD;
        MDS at any stage, based on either one of the following classifications:&#xD;
&#xD;
          -  WHO Classification&#xD;
&#xD;
          -  Refractory anemia and transfusion dependence*&#xD;
&#xD;
          -  Any of other stages&#xD;
&#xD;
          -  IPSS Classification&#xD;
&#xD;
          -  Low risk (score 0) and transfusion dependence*&#xD;
&#xD;
          -  Any other risk groups Score &gt; 0.5 Note that patients with chromosome 1q cytogenetic&#xD;
             abnormalities in the absence of morphologic dysplasia will not be considered to have&#xD;
             MDS.&#xD;
&#xD;
             3. Acute Myelogenous Leukemia Patients with acute leukemia are included in this trial&#xD;
             untreated, in remission or with refractory or relapsed disease.&#xD;
&#xD;
             * Transfusion dependence will be defined as greater than ONE transfusion of platelets&#xD;
             or red blood cells in the last year prior to evaluation on protocol.&#xD;
&#xD;
        Donor&#xD;
&#xD;
        Donor choices will be determined by the investigators according to institutional criteria.&#xD;
        Patients who will be enrolled on this protocol must have one of the following donor&#xD;
        choices:&#xD;
&#xD;
        HLA-compatible unrelated volunteer donors Patients who do not have a related HLA-matched&#xD;
        donor but have an unrelated donor who is either matched at all A, B, C and DRB1 (8/8) loci&#xD;
        or who is mismatched at no more than 2/8 loci (A, B, C or DRB1) (6/8) as tested by DNA&#xD;
        analysis (high resolution), will be eligible for entry on this protocol.&#xD;
&#xD;
        HLA-mismatched Related donors Patients who do not have a related or unrelated&#xD;
        HLA-compatible donor must have a healthy family member who is at least HLA-haplotype&#xD;
        identical to the recipient. First degree related donors must have a normal DEB test.&#xD;
&#xD;
        The donor must be healthy and willing and able to receive a 4-6 day course of G-CSF and&#xD;
        undergo 1-3 daily leukaphereses, as per institutional guidelines.&#xD;
&#xD;
        Related and unrelated donors must be medically evaluated and fulfill the criteria for&#xD;
        collection of PBSCs as per institutional guidelines.&#xD;
&#xD;
        Patients and donors may be of either gender or any ethnic background. Patients must have a&#xD;
        Karnofsky adult, or Lansky pediatric performance scale status ≥ 70%.&#xD;
&#xD;
        Patients must have adequate physical function measured by :&#xD;
&#xD;
          1. Cardiac: asymptomatic or if symptomatic then 1) LVEF at rest must be ≥ 50% and must&#xD;
             improve with exercise or 2) Shortening Fraction ≥ 29%&#xD;
&#xD;
          2. Hepatic: &lt; 5 x ULN alanine transaminase (ALT) and &lt; 2.0 mg/dl total serum bilirubin.&#xD;
&#xD;
          3. Renal: serum creatinine ≤1.5 mg/dl or if serum creatinine is outside the normal range,&#xD;
             then CrCl &gt; 50 ml/min/1.73 m^2&#xD;
&#xD;
          4. Pulmonary: asymptomatic or if symptomatic, DLCO &gt; 50% of predicted (corrected for&#xD;
             hemoglobin) Each patient must be willing to participate as a research subject and must&#xD;
             sign an informed consent form. Parent or legal guardians of patients who are minors&#xD;
             will sign the informed consent form. Assents will be obtained as per institutional&#xD;
             guidelines.&#xD;
&#xD;
        Female patients and donors must not be pregnant or breastfeeding at the time of signing&#xD;
        consent. Women must be willing to undergo a pregnancy test prior to transplant and avoid&#xD;
        becoming pregnant while on study. Positive pregnancy test results will be reported to the&#xD;
        parent(s) or guardian of minor participants, as required per institutional guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Active CNS leukemia Female patients who are pregnant (positive serum or urine HCG) or&#xD;
        breast-feeding. Women of childbearing age must avoid becoming pregnant while on study.&#xD;
&#xD;
        Active uncontrolled viral, bacterial or fungal infection Patient seropositive for HIV-I/II;&#xD;
        HTLV -I/II&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farid Boulad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Stem Cell Transplant</keyword>
  <keyword>busulfan</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>fludarabine</keyword>
  <keyword>17-498</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

